ASH 2020: Dr. Peter Hillmen on the CLARITY Trial of Ibrutinib Plus Venetoclax for Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) At the annual meeting of the American Society of Hematology (ASH) 2020, Dr. John Pagel of the CLL Society Board... August 1, 20212020 ConferencesBy Brad Hedrick
ASH 2020: Dr. Lindsey Roeker on COVID-19 Vaccine Efficacy in Patients with Chronic Lymphocytic Leukemia (CLL) At the annual meeting of the American Society of Hematology (ASH) 2020, our own Dr. Brian Koffman interviewed Dr. Lindsey... July 19, 20212020 Conferences, C19 - Updates, COVID-19By Brad Hedrick
ASH 2020: Dr. Lindsey Roeker on Epcoritamab, a Bispecific Antibody for Relapsed Chronic Lymphocytic Leukemia (CLL) At the annual meeting of the American Society of Hematology (ASH) 2020, our own Dr. Brian Koffman interviewed Dr. Lindsey... July 15, 20212020 ConferencesBy Brad Hedrick
EHA 2021: Dr. Anthony Mato on pirtobrutinib (LOXO-305) for Richter’s transformation in chronic lymphocytic leukemia (CLL) At the annual meeting of the European Hematology Association (EHA) 2021, our own Dr. Brian Koffman interviewed Dr. Anthony Mato,... July 8, 20212021 ConferencesBy Brad Hedrick
ASH 2020: Dr. Allan Discusses Front-line Ibrutinib Treatment for High-Risk Chronic Lymphocytic Leukemia (CLL) Patients In this video, Dr. John N. Allan, M.D., an Assistant Professor of Medicine at Weill Cornell Medicine and a CLL... July 8, 20212020 ConferencesBy Brad Hedrick
ASH 2020: Dr. Davids Discusses Treatment Strategies for Chronic Lymphocytic Leukemia (CLL) In this video, Dr. Matthew Davids, M.D., an Associate Professor of Medicine at Harvard Medical School and the Director of... July 2, 20212020 ConferencesBy Brad Hedrick
ASH 2020: Dr. Davids Discusses Duvelisib and Venetoclax, an All-Oral Time-Limited Treatment for Chronic Lymphocytic Leukemia (CLL) The team at Dana-Farber Cancer Institute is testing whether the combination of duvelisib (Copiktra™) and venetoclax (Venclexta®) will lead to... June 24, 20212020 ConferencesBy Brad Hedrick
ASH 2020: Dr. Furman Discusses Minimal Residual Disease-Driven Captivate and Murano Studies in Chronic Lymphocytic Leukemia (CLL) The treatment landscape for those of us with CLL/SLL has changed dramatically in the past decade or less. We see... June 24, 20212020 Conferences, MRD & Disease MonitoringBy Brad Hedrick
ASH 2020: Dr. Paolo Ghia on the Benefits of Individualized Treatment Plans for Chronic Lymphocytic Leukemia (CLL) At the annual meeting of the American Society of Hematology (ASH) 2020, our own Dr. Brian Koffman interviewed Dr. Paolo... June 17, 20212020 Conferences, MRD & Disease MonitoringBy Brad Hedrick
ASH 2020: Dr. John Allan on Bispecific Antibodies for Chronic Lymphocytic Leukemia (CLL) ASH 2020: Dr. John Allan on Bispecific Antibodies for Chronic Lymphocytic Leukemia (CLL) ... June 11, 20212020 Conferences, Conference CoverageBy Brad Hedrick
